Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Research analysts at Leerink Partnrs reduced their Q4 2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Analysts at Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for 908 Devices in a note issued to ...

In a report released on January 16, David Risinger from Leerink Partners maintained a Buy rating on AnaptysBio (ANAB – Research Report). The ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health ...

Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...